Literature DB >> 27402565

Progress towards achieving hepatitis B control in the Cook Islands, Niue, Tokelau, and Kiribati.

Minal K Patel1, Kathleen Wannemuehler2, Rangi Tairi3, Rufina Tutai4, Edna Moturi5, Beia Tabwaia6, Akineti Bauro Nikuata7, Malae Fepuleai Etuale8, Grizelda Mokoia9.   

Abstract

BACKGROUND: Hepatitis B virus (HBV) is highly endemic in many of the Pacific Island countries. Four island countries-Cook Islands, Kiribati, Niue, and Tokelau-sought to evaluate the success of their hepatitis B vaccination programs by conducting nationally representative serosurveys among children born post-vaccine introduction.
METHODS: Cook Islands, Niue, and Tokelau conducted school-based census serosurveys because of small populations. The Cook Islands tested children in second grade; Niue tested children in early childhood education through sixth grade; and Tokelau tested children in first through sixth grades. Because Kiribati has a much larger birth cohort, it conducted a one-stage stratified serosurvey among first grade students. All four countries tested children using the Alere Determine™ rapid point of care hepatitis B surface antigen (HBsAg) test.
RESULTS: In the three smaller countries, no children were seropositive for HBsAg (0/245 Cook Island students, 0/183 Niuean students, 0/171 Tokelau students). In Kiribati, 39 (3.3%, 95% confidence interval 2.4-4.6%) of 1249 students were HBsAg positive. Vaccination data collected in the Cook Islands and Tokelau showed high vaccination coverage in both countries with ⩾95% birth dose coverage and 100% 3-dose coverage.
CONCLUSIONS: The Cook Islands, Niue, and Tokelau have made remarkable progress in establishing strong vaccination programs and towards decreasing the burden of hepatitis B among children. Kiribati still needs to improve vaccination coverage to achieve the <1% HBsAg target established by the World Health Organization Western Pacific Region. Published by Elsevier Ltd.

Entities:  

Keywords:  Cook Islands; Hepatitis B; Kiribati; Niue; Tokelau; Vaccination

Mesh:

Year:  2016        PMID: 27402565      PMCID: PMC8735872          DOI: 10.1016/j.vaccine.2016.06.083

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity.

Authors:  J J Ott; G A Stevens; J Groeger; S T Wiersma
Journal:  Vaccine       Date:  2012-01-24       Impact factor: 3.641

2.  The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu.

Authors:  N Wilson; T A Ruff; B J Rana; J Leydon; S Locarnini
Journal:  Vaccine       Date:  2000-07-01       Impact factor: 3.641

3.  Prevalence of hepatitis B surface antigen and antibody in the Cook Islands with reference to difference in rates between islands.

Authors:  K Hiraiwa; Y Kuroda; M Itoh; K Katoh
Journal:  Fukushima J Med Sci       Date:  1987-12

4.  The occurrence of hepatitis B antigen and antibody in some population groups in the southwest Pacific region.

Authors:  F J Austin; T Maguire; J A Miles
Journal:  Am J Trop Med Hyg       Date:  1974-05       Impact factor: 2.345

Review 5.  Hepatitis B control in the World Health Organization's Western Pacific Region: targets, strategies, status.

Authors:  Karen Hennessey; Jorge Mendoza-Aldana; Benjamin Bayutas; Kayla Mae Lorenzo-Mariano; Sergey Diorditsa
Journal:  Vaccine       Date:  2013-12-27       Impact factor: 3.641

6.  Evaluation of rapid diagnostic tests for the detection of human immunodeficiency virus types 1 and 2, hepatitis B surface antigen, and syphilis in Ho Chi Minh City, Vietnam.

Authors:  T X Lien; N T Tien; G F Chanpong; C T Cuc; V T Yen; R Soderquist; K Laras; A Corwin
Journal:  Am J Trop Med Hyg       Date:  2000-02       Impact factor: 2.345

7.  Serological markers of hepatitis B infection in Niue children.

Authors:  H G Williamson; I D Gust; M Dimitrakakis; S Q Liu; R Taylor; J Whitmore; H T Nemaia; J Nemaia
Journal:  N Z Med J       Date:  1985-04-24

8.  A cross sectional study of markers of hepatitis B infection in Niue.

Authors:  H Zhuang; A G Coulepis; I D Gust; P Zimmet; R Taylor; H T Nemaia
Journal:  N Z Med J       Date:  1983-05-11

9.  Hepatitis B vaccines: WHO position paper--recommendations.

Authors: 
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

10.  HTLV-1, HIV-1, hepatitis B and hepatitis delta in the Pacific and South-East Asia: a serological survey.

Authors:  R J Brindle; R P Eglin; A J Parsons; A V Hill; J B Selkon
Journal:  Epidemiol Infect       Date:  1988-02       Impact factor: 2.451

View more
  2 in total

Review 1.  Cancer control in the Pacific: big challenges facing small island states.

Authors:  Diana Sarfati; Rachel Dyer; Filipina Amosa-Lei Sam; Michael Barton; Freddie Bray; Eka Buadromo; Alec Ekeroma; Sunia Foliaki; James Fong; Josephine Herman; Linda Huggins; Kiki Maoate; Ineke Meredith; Glen Mola; Neal Palafox; Viliami Puloka; Hai-Rim Shin; Jane Skeen; Wendy Snowdon; Malama Tafuna'i; Andrea Teng; David Watters; Paula Vivili
Journal:  Lancet Oncol       Date:  2019-08-05       Impact factor: 41.316

2.  Population-wide active case finding and prevention for tuberculosis and leprosy elimination in Kiribati: the PEARL study protocol.

Authors:  Mikaela Coleman; Jeremy Hill; Eretii Timeon; Alfred Tonganibeia; Baraniko Eromanga; Tauhid Islam; James M Trauer; Stephen T Chambers; Amanda Christensen; Greg J Fox; Guy B Marks; Warwick J Britton; Ben J Marais
Journal:  BMJ Open       Date:  2022-04-12       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.